Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 294-306

  Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

combination lipid therapy; fenofibrate; fibrate; mixed dyslipidemia; residual cardiovascular risk

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; LIVER MICROSOME METABOLISM; MONOTHERAPY; MYOPATHY; PRACTICE GUIDELINE; RHABDOMYOLYSIS; RISK MANAGEMENT;

EID: 41649098889     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.02.004     Document Type: Note

References (72)

1. Wilson P. High-density lipoprotein, low-density lipopro-tein and coronary artery disease. AmJ Cardiol 66 (1990) 7A-10A
2. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. Smith S.J., Allen J., Blair S., et al., AHA/ACC and the National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute [published correction appears in Circulation. 2006;113:e847]. Circulation 113 (2006) 2363-2372
4. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
5. Buse J., Ginsberg H., Bakris G., et al., American Heart Association and the American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115 (2007) 114-126
6. Grundy S., Hansen B., Smith S.J., et al., American Heart Association; the National Heart, Lung, and Blood Institute; and the American Diabetes Association. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 109 (2004) 551-556
7. Baigent C., Keech A., Kearney P., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]. Lancet 366 (2005) 1267-1278
8. Cannon C., Braunwald E., McCabe C., et al., Prava-statin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N EnglJ Med. 2006;354:778]. N EnglJ Med 350 (2004) 1495-1504
9. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
10. Deedwania P., Barter P., Carmena R., et al., Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
11. Grundy S., Cleeman J., Merz C., et al., National Heart, Lung, and Blood Institute; the American College of Cardiology; and the American Diabetes Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
12. Hayward R., Hofer T., and Vijan S. Narrative review: Lack of evidence for recommended low-density lipopro-tein treatment targets: A solvable problem. Ann Intern Med 145 (2006) 520-530
13. Modest G. Lack of evidence for recommended low-density lipopro-tein cholesterol treatment targets. Ann Intern Med 146 (2006) 614 author reply 614-615
14. Rubins H., Robins S., Collins D., et al., Department of Veterans Affairs HDL Intervention Trial Study Group. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol 75 (1995) 1196-1201
15. Alsheikh-Ali A., Karas R., Kuvin J., et al. Prevalence of low high-density lipoprotein cholesterol in ambulatory patients with coronary heart disease (CHD) or CHD risk equivalents. J Am Coll Cardiol 49 Suppl A (2007) 1020-1162 Abstract.
16. Ford E., Giles W., and Dietz W. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
17. Jacobson T., Case C., Roberts S., et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab 6 (2004) 353-362
18. Gordon T., Castelli W., Hjortland M., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. AmJ Med 62 (1977) 707-714
19. Gordon D., Probstfield J., Garrison R., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
20. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 Incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
21. Cui Y., Blumenthal R., Flaws J., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 (2001) 1413-1419
22. Ridker P., Rifai N., Cook N., et al. Non-HDL cholesterol, apolipopro-teins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
23. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 20 (1997) 1683-1687
24. von Eckardstein A., Schulte H., and Assmann G. Risk for diabetes melli-tus in middle-aged Caucasian male participants of the PROCAM study: Implications for the definition of impaired fasti ng glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 85 (2000) 3101-3108
25. St-Pierre A., Cantin B., Dagenais G., et al. Low-density lipoprotein sub-fractions and the long-term risk of ischemic heart disease in men: 13-Year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
26. Packard C. Triacylglycerol-rich lipo-proteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
27. Kontush A., and Chapman M. Functionally defective high-density lipopro-tein: A new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 58 (2006) 342-374
28. Drexel H., Aczel S., Marte T., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 28 (2005) 101-107
29. Haffner S., Alexander C., Cook T., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
30. Goldberg R., Mellies M., Sacks F., et al., CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 98 (1998) 2513-2519
31. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simva-statin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
32. Colhoun H., Betteridge D., Dur-rington P., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorva-statin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
33. Jones P., Davidson M., Stein E., et al., STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorva-statin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 92 (2003) 152-160
34. LaRosa J., Grundy S., Waters D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N EnglJMed 352 (2005) 1425-1435
35. Pedersen T., Faergeman O., Kastelein J., et al., Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial [published correction appears in JAMA. 2005;294:3092]. JAMA 294 (2005) 2437-2445
36. Nicholls S., Tuzcu E., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
37. Birjmohun R., Hutten B., Kastelein J., and Stroes E. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
38. Stone N., Bilek S., and Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol 96 (2005) 53E-59E
39. Feher M., Caslake M., Foxton J., et al. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micro-nised fenofibrate. Diabetes Metab Res Rev 15 (1999) 395-399
40. Vakkilainen J., Steiner G., DAIS Group, Ansquer J., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
41. Chapman M. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
42. Rubins H., Robins S., Collins D., et al., Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Tri al Stu dy Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N EnglJ Med 341 (1999) 410-418
43. Secondary prevention by raising HDL cholesterol and reducing triglycer-ides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
44. Meade T., Zuhrie R., Cook C., and Cooper J. Bezafibrate in men with lower extremity arterial disease: Randomised controlled trial. BMJ 325 (2002) 1139
45. Rubins H., Robins S., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
46. Arcavi L., Behar S., Caspi A., et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: Results from the Bezafibrate Infarction Prevention (BIP) study. AmHeartJ 147 (2004) 239-245
47. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study [published correction appears in Lancet. 2001;357:1890]. Lancet 357 (2001) 905-910
48. Saha S., Arora R., Bah ekar A., and Kizhakepunnur L. Fibrates in the prevention of cardiovascular events in dyslipidemic patients: A meta-analysis of randomized placebo-controlled clinical trials. J Am Coll Cardiol 49 (2007) 1002-1012 Abstract
49. Keech A., Simes R., Barter P., et al., FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial [published corrections appear in Lancet. 2006;368:1415 and Lancet. 2006;368:1420]. Lancet 366 (2005) 1849-1861
50. Burgess D., Hunt D., Li L., et al., FIELD Study Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 116 (2007) II-838
51. Ansquer J., Foucher C., Rattier S., et al., DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). AmJKidneyDis 45 (2005) 485-493
52. Keech A., Mitchell P., Summanen P., et al., FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370 (2007) 1687-1697
53. Ballantyne C., Corsini A., Davidson M., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
54. Rosenson R. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
55. Alsheikh-Ali A., Kuvin J., and Karas R. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
56. Jones P., and Davidson M. Reporting rate of rhabdomyolysis with fenofi-brate + statin versus gemfibrozil + any statin. AmJ Cardiol 95 (2005) 120-122
57. Prueksaritanont T., Tang C., Qui Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
58. Prueksaritanont T., Subramanian R., Fang X., et al. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 30 (2002) 505-512
59. Corsini A., Bellosta S., and Davidson M. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 96 (2005) 44K-49K discussion 34K-35K
60. Bergman A., Murphy G., Burke J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44 (2004) 1054-1062
61. Gustavson L., Schweitzer S., Koehne-Voss S., et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol 45 (2005) 947-953
62. Pan W., Gustavson L., Achari R., et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40 (2000) 316-323
63. Martin P., Dane A., Schneck D., and Warwick M. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25 (2003) 459-471
64. Davidson M., Armani A., McKenney J., and Jacobson T. Safety considerations with fibrate therapy. Am J Cardiol 99 (2007) 3C-18C
65. Kosoglou T., Statkevich P., Fruchart J., et al. Pharmacodynamic and pharma-cokinetic interaction between fenofi-brate and ezetimibe. Curr Med Res Opin 20 (2004) 1197-1207
66. McKenney J., Farnier M., Lo K., et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
67. Grundy S., Vega G., Yuan Z., et al. Effectiveness and tolerability of sim-vastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) [published correction appears in Am J Cardiol. 2006;98:427-428]. Am J Cardiol 95 (2005) 462-468
68. Ath yros V., Papageorgiou A., Athyrou V., et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 25 (2002) 1198-1202
69. Vega G., Ma P., Cater N., et al. Effects of adding fenofibrate (200 mg/ day) to simvastatin (10 mg/day) in patients with combined hyperlipi-demia and metabolic syndrome. Am J Cardiol 91 (2003) 956-960
70. Derosa G., Cicero A., Bertone G., et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coro- nary heart disease: A 12-month, randomized, double-blind, controlled trial. Clin Ther 26 (2004) 1599-1607
71. Ellen R., and McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 81 (1998) 60B-65B
72. Action to Control Cardiovascular Risk in Diabetes (ACCORD)[Clinicaltrials.gov Web site]. http://www.clinicaltrials.gov/ct/show/NCT00000620. Accessed April 20, 2007